Mark L. Fuerst, Author at Oncology Nurse Advisor

Mark L. Fuerst, Author at Oncology Nurse Advisor https://www.oncologynurseadvisor.com Fri, 13 Oct 2023 20:33:26 +0000 en-US hourly 1 https://wordpress.org/?v=6.4.3 https://www.oncologynurseadvisor.com/wp-content/uploads/sites/13/2024/01/cropped-CTA-ONA-HEM-favicon-32x32.png Mark L. Fuerst, Author at Oncology Nurse Advisor https://www.oncologynurseadvisor.com 32 32 With Twitter (Now X) in Flux, Is #MedTwitter Under Threat? https://www.oncologynurseadvisor.com/home/cancer-types/general-oncology/with-twitter-now-x-in-flux-is-medtwitter-under-threat/ Thu, 17 Aug 2023 15:00:00 +0000 https://www.oncologynurseadvisor.com/?p=109840

Oncology professionals share what #MedTwitter means to them and where they might go if Twitter (now X) becomes obsolete.]]> Less Than Half of NSCLC Patients Received Comprehensive Biomarker Testing in a Real-World Study https://www.oncologynurseadvisor.com/home/cancer-types/lung-cancer/lung-cancer-nsclc-less-half-patients-received-biomarker-testing/ Thu, 08 Jul 2021 13:00:00 +0000 https://www.oncologynurseadvisor.com/?p=93127 There have been some concerns that the immunomodulatory effect of PD-1 blockade may influence the response of patients with cancer to COVID-19.

There have been some concerns that the immunomodulatory effect of PD-1 blockade may influence the response of patients with cancer to COVID-19.

Most patients had at least 1 biomarker test, but only 46% had all 5 biomarker tests.]]> Perioperative Chemotherapy Matches Neoadjuvant Multimodal Therapy for Esophageal Cancer https://www.oncologynurseadvisor.com/home/headlines/conference-coverage/asco-2021/esophageal-cancer-chemotherapy-matches-neoadjuvant-therapy-risk/ Sun, 06 Jun 2021 16:10:53 +0000 https://www.oncologynurseadvisor.com/?p=92301 Cytology of esophageal adenocarcinoma.

Researchers found that CROSS is not inferior to MAGIC/FLOT, supporting it’s place in decision making for patients with locally advanced esophageal cancer.]]> Immunotherapy, Chemotherapy Combination Improves Survival in Advanced Esophageal Cancer https://www.oncologynurseadvisor.com/home/headlines/conference-coverage/asco-2021/esophageal-cancer-escc-chemotherapy-pronosis-current-immunotherapy/ Sun, 06 Jun 2021 14:35:13 +0000 https://www.oncologynurseadvisor.com/?p=92286 In this interim analysis, PFS rates were compared in PD-L1–defined biomarker subsets of patients receiving maintenance durvalumab or capecitabine.

In this interim analysis, PFS rates were compared in PD-L1–defined biomarker subsets of patients receiving maintenance durvalumab or capecitabine.

Researchers have identified a potentially new first-line treatment option for patients with advanced or metastatic esophageal squamous cell carcinoma.]]> Data Support Nivolumab Plus Chemo as Standard First-Line Therapy for Advanced Gastric, Esophageal Cancers https://www.oncologynurseadvisor.com/home/headlines/conference-coverage/asco-2021/gastric-esophageal-cancer-nivolumab-data-support-chemo-standard-care/ Sun, 06 Jun 2021 14:34:21 +0000 https://www.oncologynurseadvisor.com/?p=92289 Gastric Cancer and the Link to Helicobacter Pylori Infection

Gastric Cancer and the Link to Helicobacter Pylori Infection

Nivolumab plus chemotherapy improved overall survival.]]> Update Supports Adjuvant Nivolumab as Standard Care in Resected Esophageal or Gastroesophageal Junction Cancer https://www.oncologynurseadvisor.com/home/headlines/conference-coverage/asco-2021/nivolumab-esophageal-cancer-update-standard-care-treatment-risk/ Sun, 06 Jun 2021 14:33:48 +0000 https://www.oncologynurseadvisor.com/?p=92291 The diagnosis of linitis plastica, a subtype of gastric adenocarcinoma with a poor prognosis, can be

The diagnosis of linitis plastica, a subtype of gastric adenocarcinoma with a poor prognosis, can be

Adjuvant nivolumab prolonged distant metastasis-free survival.]]>